[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"persistent-pulmonary-hypertension-of-newborn\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:persistent-pulmonary-hypertension-of-newborn":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,43,68],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":16,"targetDuration":4,"studyType":19,"phases":20,"briefSummary":22,"conditions":23,"keywords":27,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100658259","effect-of-melatonin-on-pulmonary-hypertension-in-full-term-neonates-100658259",false,"NCT07850934","Effect of Melatonin on Pulmonary Hypertension in Full Term Neonates","Inclusion criteria :\n\n* Term neonates with gestational age ≥ 37 weeks.\n* Mean Pulmonary artery pressure greater than 25mmHg with clinical manifestations as tachypnea, tachycardia, hypoxemia and hypotension\n\nExclusion criteria :\n\n* Congenital methemoglobinemia.\n* Major congenital cardiac anomalies especially duct dependent systemic circulation.\n* Bleeding tendency.\n* Patients on other pulmonary vasodilators","ALL",{"count":17,"type":18},52,"ESTIMATED","INTERVENTIONAL",[21],"NA","The aim of the study\n\n1. To evaluate safety and efficacy of melatonin as an adjuvant therapy to inhaled nitric oxide generated by NO generator in the treatment of pulmonary hypertension in full term neonates.\n2. To assess the effect of inhaled nitric oxide and melatonin on cerebral perfusion.",[24,25,26],"Congenital Peumonia","Persistent Pulmonary Hypertension of Newborn","Congenital Diaphragmatic Hernia",[28,29],"Nitric oxide generator","Melatonin","RECRUITING","2026-09-28",{"date":33,"type":34},"2026-09-30","ACTUAL",{"date":36,"type":34},"2025-07-01",{"date":38,"type":18},"2026-12-01",{"name":40,"class":41},"Ain Shams University","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":67},"100554459","treprostinil-in-newborns-with-pulmonary-hypertension-a-non-interventional-study-to-collect-data-on-drug-utilization-safety-and-effectiveness-100554459","NCT06499363","Treprostinil in Newborns With Pulmonary Hypertension; a Non-Interventional Study to Collect Data on Drug Utilization, Safety, and Effectiveness","Treprostinil in Newborns With Pulmonary Hypertension; a Noninterventional Study to Collect Data on Drug Utilization, Safety, and Effectiveness.","NEPHY","Inclusion Criteria:\n\n1. Newborn infants who received at least one dose of IV or SC treprostinil as per clinical practice within 5 years from the moment of data collection.\n2. Aged up to 44 weeks after conception at treprostinil initiation.\n3. Pulmonary hypertension (PH) or suspicion of PH at the moment of treprostinil initiation.\n4. Parent(s) or legally authorized representative(s) provides non-opposition consent for the patient participation in the study.\n5. Newborn infants affiliated to French social security.\n\nExclusion Criteria:\n\n* None.","44 Weeks",{"count":53,"type":18},60,"OBSERVATIONAL","This observational study will seek to describe the uses and safety and efficacy outcomes of treprostinil in clinical practice in patients with persistent pulmonary hypertension (PPHN).",[25],"2025-09-02",{"date":59,"type":34},"2025-09-03",{"date":61,"type":34},"2025-02-25",{"date":63,"type":18},"2027-12-31",{"name":65,"class":66},"Ferrer Internacional S.A.","INDUSTRY",4,{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":15,"minAge":75,"maxAge":76,"enrollmentInfo":77,"targetDuration":4,"studyType":19,"phases":79,"briefSummary":82,"conditions":83,"keywords":84,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":42},"100431440","phase-1-nebulized-magnesium-sulfate-and-sildenafil-for-persistent-pulmonary-hypertension-of-newborn-100431440","NCT04898114","Nebulized Magnesium Sulfate and Sildenafil for Persistent Pulmonary Hypertension of Newborn","Effectiveness of Nebulized Magnesium Sulfate Combined With Sildenafil Citrate in Persistent Pulmonary Hypertension of Newborn","Inclusion Criteria:\n\n* Gestational age ≥ 36 weeks\n* Birth weight between 2.5 and 4 kg.\n* Post-natal age between 6 and 72 hours.\n* PPHN confirmed by echocardiography\n* Oxygenation index (OI) \\> 30 on two occasions at least 15 minutes apart\n* Connected to Mechanical Ventilation\n\nExclusion Criteria:\n\n* Failure to obtain informed consent\n* Newborns to mothers who received magnesium sulfate within 48 hours before labor.\n* Congenital heart diseases, other than patent ductus arteriosus and foramen ovale.\n* Major congenital anomalies (including congenital diaphragmatic hernia and lung hypoplasia).\n* Prior need for cardiopulmonary resuscitation.\n* Mean arterial blood pressure (MABP) \\\u003C 35 mmHg despite therapy with volume infusions and vasoactive inotropes.\n* Impaired kidney function.\n* Prior administration of pulmonary vasodilators.\n* Gastrointestinal intolerance or bleeding","6 Hours","72 Hours",{"count":78,"type":18},40,[80,81],"PHASE1","PHASE2","The aim of this study is to evaluate the effectiveness of nebulized magnesium sulfate combined with sildenafil citrate, compared with sildenafil citrate alone, in treating neonates with severe persistent pulmonary hypertension on mechanical ventilation.",[25],[85,86,87,88,89,90,91,92],"neonate","persistent fetal circulation","persistent pulmonary hypertension of the newborn","PPHN","Magnesium Sulfate","Nebulizer","hypoxia","mechanical ventilation","2024-11-26",{"date":95,"type":34},"2024-11-27",{"date":97,"type":34},"2021-06-02",{"date":99,"type":18},"2025-06-01",{"name":101,"class":41},"Sohag University"]